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Abstract

Much remains unknown about the impact of initial antibiotic adequacy on mortality in community onset bacterial pneumonia
(COBP). Therefore, we performed a study to determine how the adequacy of initial antibiotic therapy affects in-hospital mortality for
patients with COBP.
We carried out a retrospective cohort study among the 11 BJC Healthcare community and academic hospitals in Missouri and
Illinois. The electronic medical records for BJC Healthcare were queried to obtain a set of patient admissions with culture positive
(respiratory or blood) COBP admitted from January 1, 2016 through December 31, 2019. Patients with COBP required an
International Classiﬁcation of Diseases (ICD)-10 diagnostic code for pneumonia, admission to the hospital through an emergency
department, a chest radiograph with an inﬁltrate, an abnormal white blood cell count or temperature, an order for 1 or more new
antibiotics, and a positive respiratory or blood culture. Antibiotic selection was deemed adequate if the patient had organisms
susceptible to at least one of the antibiotics received according to in vitro testing using standard laboratory breakpoints.
Among 36,645 screened pneumonia admissions, 1843 met criteria for culture positive COBP. Eight hundred nineteen (44.4%)
had ceftriaxone-resistant (CTX-R) organisms and 1024 had ceftriaxone-sensitive (CTX-S) organisms. The most common CTX-R
pathogens were methicillin resistant Staphylococcus aureus (46.9%), Pseudomonas species (38.4%), and Escherichia coli (4.5%).
On the day of admission 71% of all patients were given adequate antibiotic treatment (62.2% of CTX-R and 77.9% of CTX-S).
Unnecessarily broad initial treatment was administered to 57.1% of CTX-S patients. In a logistic regression model accounting for
comorbidities and severity of illness, inadequate therapy on the day of admission was associated with higher in-hospital mortality
(P = .005). Among CTX-S patients who were adequately treated, initial use of unnecessarily broad antibiotics was associated with
increased in-hospital mortality (P = .003).
Ceftriaxone resistance was common in this cohort of culture positive COBP patients. Inappropriate coverage on day of admission
was associated with greater likelihood of in-hospital mortality.
Abbreviations: CAP = community acquired pneumonia, COBP = community onset bacterial pneumonia, CTX-R = ceftriaxone
resistant, CTX-S = ceftriaxone sensitive, IDSA/ATS = Infectious Diseases Society of America/American Thoracic Society, MDR =
multidrug resistant, MRSA = methicillin resistant Staphylococcus aureus.
Keywords: adequate initial therapy, antibiotics, ceftriaxone resistance, community onset, pneumonia

1. Introduction

hospitalizations annually.[1] Though a precise microbiologic
etiology is not established in a majority of cases,[2–4] there has
been a notable increase in the prevalence of multidrug resistant
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(MDR) bacteria in patients presenting from the community.[5]
Exact ﬁgures for antibiotic resistance vary based on the
population studied, ranging for 6% of CAP patients overall
to 46.7% of patients admitted with proven bacterial pneumonia.[6,7]
Choosing empiric therapy for hospitalized patients with
pneumonia arising outside of the hospital setting poses a
challenge due to greater overall rates of infection with MDR
pathogens. Clinicians need to treat for MDR organisms when
present, yet overuse of broad spectrum antibiotics will escalate
drug resistance. Furthermore, broad spectrum antibiotic use in
CAP has been associated with greater mortality, thought to be
driven in part by the increased incidence of Clostridium difﬁcile
infection complicating the treatment of CAP.[8] The rise of MDR
organisms in CAP is reﬂected in current prescribing patterns for
initial antibiotic therapy of CAP. For example, rates of
vancomycin administration for CAP doubled between 2000
and 2009.[9] The 2019 combined Infectious Diseases Society of
America (IDSA)/American Thoracic Society (ATS) guidelines on
CAP recognize this dilemma and recommend treatment with a
beta-lactam (such as a third generation cephalosporin) as part of
empiric therapy for hospitalized patients.[10] However, IDSA/
ATS guidance on empiric treatment for MDR organisms such as
methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa is less clear, with the authors recommending
that clinicians take into account the severity of illness and
“locally validated” risk factors.[10]
Inadequate antibiotic therapy for patients with sepsis and
septic shock has been shown to be associated with excess
mortality.[11–14] Similarly, patients with CAP due to antibiotic
resistant bacteria have a greater risk of mortality when treated
with inadequate initial antibiotics.[15] A study of 94 CAP
patients found that individuals receiving initial antibiotics that
were inconsistent with the IDSA/ATS guidelines fared worse.[16]
Among bacteremic pneumonia patients, inadequate initial
therapy was found to be common, particularly among those
with ceftriaxone-resistant (CTX-R) organisms, and was associated with higher mortality.[17] In another study involving
emergency department patients diagnosed and treated for CAP,
27.8% received inadequate antibiotics initially though no
increase in mortality was found.[18] In a French study of CAP
patients treated in an intensive care unit, adequate initial therapy
was associated with better survival at 60 days.[19] More recently,
Webb et al[20] found that inadequate initial therapy was
associated with higher mortality in a subgroup analysis of their
study of drug resistance in CAP. However, a majority of their
cohort was culture negative limiting their sample size.
Much remains unknown about the impact of initial antibiotic
adequacy on mortality in community onset bacterial pneumonia
(COBP). The objective of our study is to describe the
microbiology of COBP and to determine how adequacy of
antibiotic therapy on the day of admission affects in-hospital
mortality for culture positive cases.

healthcare systems in the United States containing 11 community
hospitals in Missouri and Illinois as well as 2 academic hospitals
afﬁliated with Washington University School of Medicine.
Washington University and BJC Healthcare have a longstanding
partnership to provide regional healthcare services. This study
was approved by the Washington University Institutional
Review Board (IRB ID# 201801189).
2.2. Participants
We applied the following criteria to select patients as having
COBP: International Classiﬁcation of Diseases (ICD)-10 diagnostic codes for pneumonia (A37.01, J13, J14, J15.x, J16.x, J18.
x, J85.1), admission to the hospital through an emergency
department, a chest radiograph with an inﬁltrate documented by
board-certiﬁed radiologists, an abnormal white blood cell count
(>11,000 cells/mL or <4000 cells/mL) or temperature, an order
for 1 or more antibiotics (ordered within 24 hours of meeting the
radiographic and clinical criteria), and a positive respiratory or
blood culture. All criteria had to be met within the ﬁrst 48 hours
of hospital admission. To further support the diagnosis of
pneumonia, a random subset of patients (≈5%, n = 100) had
their chest radiographs reviewed by an investigator (MHK)
blinded to group allocation to conﬁrm the presence of new
consolidations on the chest radiograph consistent with a
diagnosis of pneumonia (>95% of reviewed cases). Patients
with cultures only growing organisms that were likely
contaminants (including Enterococcus, Candida, as well as
Salmonella, coagulase negative Staphylococcus or Corynebacterium isolated from blood) were eliminated from the analysis.
2.3. Variables of interest
Antibiotic adequacy for each patient was determined by
comparing the set of antibiotics ordered to the susceptibilities
of the organisms isolated from their blood and respiratory
cultures. Antibiotic selection was deemed adequate if the patient
had organisms susceptible to at least one of the antibiotics
received (according to in vitro testing using standard laboratory
breakpoints), while not having any organisms resistant to these
drugs. In the unusual circumstance of a patient infected with
multiple MDR organisms and receiving multiple antibiotics,
adjudication of adequacy was determined by manual review. As
not all isolates had susceptibility testing performed for all
antibiotics ordered, several inferences were used to judge
whether an antibiotic provided adequate coverage. Ciproﬂoxacin and levoﬂoxacin were considered to be equivalent; linezolid
and vancomycin were considered to be equivalent; ampicillinsulbactam and amoxicillin-clauvulanate were considered to be
equivalent; organisms susceptible to ceftriaxone, methicillin, and
cefotaxime were considered to be susceptible to carbapenems,
piperacillin-tazobactam, and cefepime; MRSA was considered to
be susceptible to vancomycin, linezolid, ceftaroline, and
doxycycline; methicillin-susceptible S aureus was considered
to be susceptible to carbapenems, ceftriaxone, cefepime,
ceftaroline, piperacillin-tazobactam, doxycycline, vancomycin,
linezolid, cefazolin, nafcillin, oxacillin, ampicillin-sulbactam,
and clindamycin.
Patients in our database were ﬁrst screened against the
deﬁnition of COBP. Then we examined their culture data for
ceftriaxone resistance dividing the patients into 2 sub-groups:
CTX-R and ceftriaxone sensitive (CTX-S). Subsequently,

2. Methods
2.1. Study design and setting
The electronic medical record system for BJC Healthcare was
queried to perform a retrospective cohort study of patients
diagnosed with pneumonia from January 1, 2016 through
December 31, 2019. BJC Healthcare is one of the largest
2
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3. Results

patients were further divided into 5 cohorts based on antibiotic
adequacy. The CTX-R group was divided into adequately and
inadequately treated, while the CTX-S group was divided into
inadequately treated, overtreated, and narrow spectrum. CTX-S
patients were designated as being “overtreated” if they had an
organism susceptible to ceftriaxone but received cefepime,
meropenem, linezolid, vancomycin, ceftaroline, ceftazidimeavibactam, or ceftolozane-tazobactam. The “narrow spectrum”
classiﬁcation signiﬁes that the patient received adequate
coverage with ceftriaxone or a quinolone.
The primary outcome for the study was in-hospital mortality.
Predictor variables of interest included age, gender, use of
vasopressors on admission, admission to intensive care unit, as
well as comorbidities as measured by the 5-year age adjusted
Charlson Comorbidity Score.[21]

3.1. Adequacy of initial antibiotic therapy lower in CTX-R
bacteria
A total of 36,645 patient-admissions were screened, with 1843
meeting all of the criteria for COBP. Figure 1 shows a ﬂowchart
for cohort generation and division into the 5 subgroups based on
antibiotic choices on the day of admission. Among patients with
COBP 819 (44.4%) had CTX-R pathogens. Overall 1308 of the
1843 COBP patients (71%) were treated adequately, including
510/819 (62.3%) of CTX-R and 798/1024 (77.9%) of CTX-S
patients. Baseline characteristics for the 5 subgroups are
presented in Table 1.
3.2. Nosocomial pathogens predominated the
microbiology of CTX-R bacteria

2.4. Statistical analysis

The most common pathogens infecting CTX-R patients were
MRSA, Pseudomonas species, and Escherichia coli as shown in
Table 2. The most common CTX-S organisms were methicillin
sensitive S aureus, Streptococcus pneumoniae, and E coli. Most
CTX-S patients were screened into the study by having positive
blood cultures while most CTX-R patients had positive
respiratory cultures.

Data analysis was performed using R (version 3.5), including the
dplyr package, as well as Microsoft Excel.[22,23] Categorical
variables were compared using chi-squared testing and continuous variables between multiple groups were analyzed with
ANOVA. An alpha of 0.05 was utilized for statistical
signiﬁcance. Two logistic regression analyses were prospectively
planned to determine patient variables associated with increased
in-hospital mortality. The ﬁrst analysis was run on the entire
cohort that included adequacy of antibiotic coverage as a
variable. A second logistic regression was planned for the
subgroup of patients with CTX-S organisms who were
adequately treated to determine effect of overtreatment on
mortality. All logistic regressions were binomial and performed
using the generalized linear model function (glm) of R version
3.5. Goodness of ﬁt testing was performed with the HosmerLemeshow test. Testing for multicollinearity was performed by
calculating the variance inﬂation factor. Sample size was a
convenience sample based on the cohort for the study period.

3.3. Broader spectrum initial antibiotic therapy prescribed
in patients with CTX-R bacteria
The distribution of CTX-R and CTX-S patients who received
each of the most prescribed antibiotics on admission is shown in
Figure 2. There were statistically signiﬁcant differences in the
administration rates of each of the 9 most prescribed antibiotics
between the CTX-R and CTX-S groups with the exception of
piperacillin-tazobactam. Antibiotic adequacy for both groups
was also analyzed on the subsequent 3 days of admission
(presumably susceptibility data would begin to become available

Figure 1. Flow-chart showing cohort generation based on antibiotics received on day of admission. There were 1843 patients meeting the study criteria for
community-onset bacterial pneumonia. These patients were divided into ceftriaxone sensitive (CTX-S) and ceftriaxone resistant (CTX-R) cohorts. These cohorts
were further divided into categories based on whether the initial antibiotic regimen was adequate or inadequate for those with CTX-R bacteria, and narrow
spectrum, overtreated, and inadequate for those with CTX-S bacteria.
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Table 1
Baseline characteristics.
CTX-R adequate
(N = 510)
Gender (M)
Age (yrs)
Race (Caucasian)
Academic hospital
On vasopressors
Intensive care unit
Charlson Comorbidity Score (5 yr age adjusted)

56.3%
61.8 (19.0)
67.3%
35.7%
20.6%
45.5%
7.1 (3.7)

∗

CTX-R inadequate† CTX-S narrow spectrum‡ CTX-S overtreatedx CTX-S inadequate¶
(N = 309)
(N = 213)
(N = 585)
(N = 226)
52.4%
65.4 (17.1)
70.2%
27.8%
10.7%
34.3%
7.1 (3.6)

42.3%
63.8 (16.1)
75.6%
11.3%
1.9%
12.2%
5.2 (3.4)

53.2%
63.9 (16.8)
65.1%
32.5%
22.9%
47.0%
6.2 (3.6)

53.1%
60.1 (16.1)
59.1%
36.7%
10.6%
37.6%
5.7 (3.7)

P
.017
.002
.003
<.001
<.001
<.001
<.001

Results for age and Charlson Comorbidity reported as mean (standard deviation). Categorical variables compared by chi-squared testing and continuous variables compared with analysis of variance.
CTX-R = ceftriaxone resistant, CTX-S = ceftriaxone sensitive.
∗
Ceftriaxone resistant organism adequately treated on day of admission.
†
Ceftriaxone resistant organism inadequately treated on day of admission.
‡
Ceftriaxone sensitive organism without cefepime, meropenem, piperacillin-tazobactam, vancomycin, linezolid, ceftaroline, ceftolozane-tazobactam, and ceftazidime-avibactam treatment on day of admission.
x
Ceftriaxone sensitive organism treated with at least one of the above listed antibiotics on day of admission.
¶
Ceftriaxone sensitive organism inadequately treated on day of admission.
Antibiotics included in the analysis: ampicillin-sulbactam, azithromycin, aztreonam, cefazolin, cefepime, ceftaroline, ceftazidime-avibactam, ceftolozane-tazobactam, ceftriaxone, ciproﬂoxacin, clindamycin,
doxycycline, ertapenem, gentamicin, levoﬂoxacin, linezolid, meropenem, nafcillin, oxacillin, piperacillin-tazobactam, and vancomycin.

for drug resistant organisms previously found in studies of CAP,
although it is important to recognize that our study is limited to
patients with a positive culture and in a majority of pneumonia
cases a positive culture is not obtained.[2–4,6,20] This value of
44.4% is similar to the 46.7% incidence of CTX-R organisms
obtained by Shorr et al[7] in our institution in their study of
culture positive pneumonia presenting through an academic
hospital emergency department. Not surprisingly, MRSA and
Pseudomonas were the predominant CTX-R organisms, though
there was notable prevalence of ceftriaxone resistance among the
enteric Gram negatives including E coli, Klebsiella species, and
Serratia species. Our study also supports a higher mortality being
associated with CTX-R organisms as shown in other studies of
outpatient pneumonia.[24–26]
It should be noted that our study cohort represents a
population with a high severity of illness, with 39.3% of
patients admitted to an intensive care unit, which is greater than
the number of patients requiring intensive care in the generalized
CAP population.[2,10] One possible explanation is that our
cohort contains only those patients with positive bacterial
cultures, and blood and respiratory cultures are more commonly

at approximately days 3–4), results of which are presented in
Table 3. A majority (57.12%) of CTX-S patients were
overtreated initially. Overtreatment peaked at day 2, while for
both groups overall adequacy of therapy increased with each day
of admission.
3.4. CTX-R bacteria associated with higher mortality
Mortality for the antibiotic treatment subgroups is shown in
Table 4. CTX-R patients had higher in-hospital mortality
compared with CTX-S patients (14.4% vs 10.2%, P = .007).
Logistic regression analyses for in-hospital mortality are
displayed in Table 5. For the overall cohort of 1843 patients,
antibiotic adequacy on admission was associated with decreased
in-hospital mortality (P < .001). For the subgroup of 798 CTX-S
patients adequately treated, overtreatment was associated with
increased in-hospital mortality (P = .003).

4. Discussion
Ceftriaxone resistance was common in this cohort affecting
44.4% of patients with COBP. This is higher than some ﬁgures
Table 2

Microbiology of ceftriaxone-sensitive and ceftriaxone-resistant bacterial.
Pathogen
Streptococcus pneumoniae
Staphylococcus aureus
Pseudomonas species
Acinetobacter species
Enterobacter species
Klebsiella species
Escherichia coli
Proteus species
Morganella morganii
Serratia species
Haemophilus inﬂuenza
Other Streptococcal species
Citrobacter species
Other

Ceftriaxone-resistant
Blood cultures (n = 279)

Respiratory cultures (n = 584)

Ceftriaxone-sensitive
Blood cultures (n = 727)

Respiratory cultures (n = 361)

0.7
58.0
20.0
1.4
2.9
1.8
10.8
0.4
0.4
2.5
–
–
–
1.1

0.2
42.3
47.8
0.9
2.7
1.0
1.5
–
–
3.1
–
–
–
0.3

27.9
24.1
–
0.7
0.7
6.6
16
3.0
0.6
0.8
1.1
17.1
0.4
1.1

39.0
38.2
–
0.3
0.8
8.6
6.4
1.6
0.3
1.4
–
1.1
0.6
1.7

Percent of patient admissions with at least 1 culture growing that organism (e.g., a patient with multiple blood cultures positive for the same pathogen during an admission is counted once).
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∗

Figure 2. Antibiotic choices on day of admission for ceftriaxone resistant (CTX-R; N = 819) vs ceftriaxone sensitive (CTX-S; N = 1024) patients. Signiﬁes
statistically signiﬁcant difference (P < .05).

Table 3
(a) Adequacy of antibiotic coverage for CTX-S and CTX-R on ﬁrst 4 days of admission. (b) Proportion of CTX-S patients who were
overtreated on the ﬁrst 4 days of admission.
(a)
CTX-S adequate coverage
CTX-R adequate coverage

Day 1

Day 2

Day 3

Day 4

798/1024 (77.9%)
509/819 (62.2%)

900/1024 (87.9%)
585/819 (71.4%)

945/1024 (92.3%)
825/819 (76.3%)

889/953 (93.4%)
644/783 (82.4%)

(b)
CTX-S overtreatment

∗

Day 1

Day 2

Day 3

Day 4

585/1024 (57.1%)

733/1024 (71.6%)

679/1024 (66.3%)

549/953 (57.7%)

CTX-R = ceftriaxone resistant, CTX-S = ceftriaxone sensitive.
∗
Subset of CTX-S patients who had a ceftriaxone-sensitive organism and were treated with cefepime, meropenem, piperacillin-tazobactam, vancomycin, linezolid, ceftaroline, ceftolozane-tazobactam, or
ceftazidime-avibactam on day of admission.

Table 4
In-hospital mortality of each subgroup. Chi-squared testing used to calculate P value.
CTX-R adequate
(N = 510)
In-hospital mortality

72 (14.1%)

∗

CTX-R inadequate†
(N = 309)

CTX-S narrow spectrum‡
(N = 213)

CTX-S overtreatedx
(N = 585)

CTX-S inadequate¶
(N = 226)

P

46 (14.9%)

5 (2.4%)

73 (12.5%)

27 (12.0%)

<.001

Chi-squared testing used to calculate P value.
CTX-R = ceftriaxone resistant, CTX-S = ceftriaxone sensitive.
∗
Ceftriaxone resistant organism adequately treated on day of admission.
†
Ceftriaxone resistant organism inadequately treated on day of admission.
‡
Ceftriaxone sensitive organism treated without cefepime, meropenem, piperacillin-tazobactam, vancomycin, linezolid, ceftaroline, ceftolozane-tazobactam, or ceftazidime-avibactam on day of admission.
x
Ceftriaxone sensitive organism treated with at least one of the above listed antibiotics on day of admission.
¶
Ceftriaxone sensitive organism inadequately treated on day of admission.
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was associated with higher in-hospital mortality. Therefore, the
initial antibiotic choice for COBP is of great importance.
However, our ﬁndings should be weighed against other studies
such as the Veterans Affairs study of Jones et al[27] ﬁnding that
initial empiric MRSA coverage for pneumonia did not impact
mortality in their population. Thus prevalence of local antibiotic
resistance, along with disease severity and patient risk factors for
infection with antibiotic resistant pathogens, are important
factors to consider when making empiric treatment decisions for
patients with CAP.[10]
The strengths of this study are that it involves a large, robust
dataset across several hospitals (both community and academic)
spanning 4 years. Furthermore, we systematically compared
each individual’s set of antibiotics to their unique culture
susceptibilities for each of the ﬁrst 4 days of admission. The
major limitation is that this cohort is restricted to those who had
positive bacterial cultures, thus affecting generalizability to the
overall community onset pneumonia population in which a
signiﬁcant proportion are culture-negative have viral etiologies.
Another limitation is that antibiotic adequacy was based on
calendar day of administration as opposed to measuring time to
antibiotic administration. Theoretically this could lead to a
misclassiﬁcation error if a patient was admitted late in the
evening and received antibiotics shortly after midnight, as this
would be counted as having inadequate initial therapy on day 1.
However, we expect this effect to be limited overall, as day 2 data
show signiﬁcant coverage gaps as well. One would also expect
this effect to be distributed equally to both CTX-R and CTX-S
groups. Another limitation of our study is that clinicians at our
institutions do not routinely employ scoring systems such as the
CARMELI score or the DRIP score.[20,28] Lastly, our classiﬁcation of patients coming in from the community as having COBP
may be imprecise as it fails to differentiate individuals with
healthcare exposure (e.g., recent hospitalization, residence in a
nursing home, use of chronic dialysis) from those without such
exposure. The most recent IDSA/ATS guidelines recommends
against using the classiﬁcation of healthcare-associated pneumonia as it may lead to greater unnecessary use of broadspectrum antibiotics.[10] Therefore, we grouped all patients as
having COBP regardless of whether or not they had some type of
healthcare exposure prior to admission.

Table 5
(a) Logistic regression analysis for in-hospital mortality for entire
cohort of 1843 patient-admissions. (b) Logistic regression
analysis for in-hospital mortality for the cohort of the 798 patients
with CTX-S pathogens receiving adequate initial antibiotic
treatment.
(a)
Variable

Estimate

Standard error

P

Academic medical center
Gender (male)
Age (yrs)
Bacteremia
Vasopressors day 1
ICU admission day 1
Charlson 5 yr (age adjusted) score
Adequate antibiotic coverage day 1

0.009
0.103
0.014
0.336
0.727
0.878
0.11
0.471

0.168
0.15
0.006
0.157
0.184
0.174
0.024
0.167

.95
.49
.02
.03
<.001
<.001
<.001
<.001

(b)
Variable

Estimate

Standard error

P

Academic medical center
Gender (male)
Age (yrs)
Bacteremia
Vasopressors day 1
ICU admission day 1
Charlson 5 yr (age adjusted) score
Overtreated

0.212
0.021
0.03
0.14
0.489
0.617
0.0608
1.44

0.294
0.249
0.011
0.301
0.305
0.293
0.042
0.488

.47
.93
.004
.63
.10
.03
.14
.003

(a) Testing for collinearity performed with by calculating the variance inﬂation factor ranging from
1.01 to 1.40 for these variables. Goodness of ﬁt testing performed with Hosmer-Lemeshow test (chi
squared 8.36 with df = 8, P = .399).
(b) Variance inﬂation factor ranged from 1.01 to 1.39 for these variables. Goodness of ﬁt testing
performed with Hosmer-Lemeshow test (chi squared 11.61 with df = 8, P = .166).
CTX-S = ceftriaxone sensitive.

obtained in those with severe illness, which is in keeping with the
2019 IDSA/ATS guidelines.[10]
As suggested by Figure 2, clinicians may have employed
criteria such as presence of comorbidities and healthcare
exposure to determine which patients harbor antibiotic resistant
organisms, as CTX-R patients were more likely to receive
empiric antibiotics to treat for resistant organisms (such as
vancomycin, meropenem, and cefepime), while CTX-S patients
were approximately twice as likely to receive empiric ceftriaxone. However, there was under treatment of CTX-R patients
with only 62.15% receiving adequate treatment initially.
Furthermore, a majority of CTX-S patients were overtreated
on all days analyzed, peaking at 77% on day 2. Table 1 also
suggests that clinicians are highly inﬂuenced by severity of illness
(as assessed by intensive care unit admission and use of
vasopressors) when deciding on the spectrum of antibiotics to
administer. There were notable similarities in the CTX-R
adequate group and the CTX-S overtreated group in terms of
vasopressor use (20.6% vs 22.9%, P = 0.35) and ICU admission
(45.5% vs 47.0%, P = 0.61). Thus, clinicians were likely treating
patients in these 2 groups with broad spectrum antibiotics based
on their disease severity. Additionally, we found underutilization
of azithromycin overall in this population, with fewer than 30%
of patients receiving it on day 1. According to the 2019 IDSA/
ATS guidelines, atypical pathogen coverage should be given
liberally to these patients.[10] The logistic regression analyses
show that adequacy of therapy on the day of admission is
inversely associated with in-hospital mortality. Furthermore,
among the adequately treated CTX-S patients overtreatment

5. Conclusions
Treating infections in the 21st century is a balancing act between
upholding antibiotic stewardship while ensuring adequate
therapy to a population with an increasing prevalence of
resistant organisms. This study shows that opportunities for
improvement in the administration of initial therapy exist and
potentially include enhanced stewardship practices, the use of
rapid microbiologic diagnostics, and the use of machine
learning/artiﬁcial intelligence derived algorithms to guide
antibiotic decision making. Further research is needed to
develop higher resolution tools to accurately predict which
patients are likely to harbor resistant organisms including the
broader use of molecular diagnostics and machine learning
prediction instruments.[29–31]
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